Amylin Pharmaceuticals, Inc.

GLP-1 receptor agonist drugs have conquered the cardiometabolic field but could be poised to play a big role in neurodegenerative diseases too. A growing number of studies suggest GLP-1 receptor agoni

Incoming Biosimilars Council Executive Director Craig Burton wants the industry and policymakers to learn from the launch of insulin biosimilars in time for the widely anticipated debut of competitors